Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle
© Kerner et al.; licensee BioMed Central. 2015
Received: 29 October 2014
Accepted: 26 March 2015
Published: 10 April 2015
Cattle are the most important reservoir for enterohemorrhagic Escherichia coli (EHEC), a subset of shigatoxigenic E. coli (STEC) capable of causing life-threatening infectious diseases in humans. In cattle, Shiga toxins (Stx) suppress the immune system thereby promoting long-term STEC shedding. First infections of animals at calves’ age coincide with the lack of Stx-specific antibodies. We hypothesize that vaccination of calves against Shiga toxins prior to STEC infection may help to prevent the establishment of a persistent type of infection. The objectives of this study were to generate recombinant Shiga toxoids (rStx1mut & rStx2mut) by site-directed mutagenesis and to assess their immunomodulatory, antigenic, and immunogenic properties. Cultures of bovine primary immune cells were used as test systems. In ileal intraepithelial lymphocytes both, recombinant wild type Stx1 (rStx1WT) and rStx2WT significantly induced transcription of IL-4 mRNA. rStx1WT and rStx2WT reduced the expression of Stx-receptor CD77 (syn. Globotriaosylceramide, Gb3) on B and T cells from peripheral blood and of CD14 on monocyte-derived macrophages. At the same concentrations, rStx1mut and rStx2mut exhibited neither of these effects. Antibodies in sera of cattle naturally infected with STEC recognized the rStxmut toxoids equally well as the recombinant wild type toxins. Immunization of calves with rStx1mut plus rStx2mut led to induction of antibodies neutralizing Stx1 and Stx2. While keeping their antigenicity and immunogenicity recombinant Shiga toxoids are devoid of the immunosuppressive properties of the corresponding wild type toxins in cattle and candidate vaccines to mitigate long-term STEC shedding by the reservoir host.
Enterohemorrhagic Escherichia coli (EHEC), a subset of Shiga toxin-producing E. coli (STEC), are food-borne pathogens which can evoke life-threatening diseases, such as hemorrhagic colitis and hemolytic-uremic syndrome, in humans. Cattle and other ruminants are primary reservoirs for EHEC serotypes that are frequently associated with human disease, e.g., EHEC O157:H7. Calves become infected with a plethora of different STEC strains early in life via horizontal or vertical transmission. Although calves rarely develop clinical signs of STEC infection they may shed these bacteria for several months and shed STEC quantities may be considerably high at some sampling points [1-4].
To prevent humans from EHEC infection, interventions must be applied at several stages of the food chain, starting in the animal itself and continuing in slaughterhouses, processing plants, distributors, and households . A systematic review of vaccinations to reduce the shedding of E. coli O157 in the faeces of domestic ruminants revealed that vaccination may be a sensible control option . Current vaccination strategies are promising but only succeed partially in reducing E. coli O157:H7 excretion (as reviewed by ). In some instances, e.g., when vaccinating cattle against H7 flagellin, an important adhesion factor to bovine intestinal epithelium during early stages of colonization , systemically induced H7-specific IgG may even impair innate immune responses to E. coli O157:H7 when getting into contact with the epithelium via neutralisation of TLR5-mediated activation of epithelial cells .
Shiga toxins (Stx) are potent protein cytotoxins and represent the principal STEC virulence factor in the pathogenesis of human infections. Cumulating evidence exist that Stx act as immunomodulating agents during STEC infections in cattle. Stx1 alters the cytokine expression pattern in mucosal macrophages  and intraepithelial lymphocytes  and suppresses the activation and proliferation of mucosal  and peripheral lymphocytes in vitro . The development of an adaptive cellular immune response is significantly delayed following experimental infection of calves with Stx2+ STEC O157:H7 compared to that in animals inoculated with Stx-negative E. coli O157:H7 . In vitro and in vivo studies revealed that Stx operate during the early phases of immune activation rather than depressing an established immunity [11-14]. Consequently, Stx likely acts as immunomodulator only upon first STEC infection of hitherto immunologically naïve calves. Of note, a significant portion of calves lacks anti-Stx antibodies at the time of first encountering STEC . We hypothesize that passive (maternal) and active vaccination against Stx1 and Stx2 confers a protection against the toxins’ immunosuppressive effects and subsequently enables the calves to actively mount a rapid immune response against STEC strains circulating in the respective cohort. Kuribayashi et al. showed that immunization of pregnant cows with Stxs led to an enrichment of colostra with anti-Stx1 and anti-Stx2 antibodies . Subsequent application of bovine colostral anti-Stx2 to experimentally infected dogs indeed reduced STEC shedding .
Development of anti-Stx antibodies is remarkably delayed after natural  and experimental STEC infection of cattle . Although Stx primarily targets CD8+ cells , the immunomodulating capacity of Stx may also impair the humoral anti-Stx response. A strategy to circumvent this obstacle is the use of toxoid vaccines. Chemically inactivated Stx2e, however, was only partially effective in protecting piglets against oedema disease . A more promising approach is the inactivation of Stx by genetic modification. Replacement of amino acids E167 and R170, located within the enzymatically active cleft of Stx2e [19,20] and vaccination of piglets with the recombinant protein fully protected piglets during challenge with native Stx2e . Similar results have been reported for mice [22,23].
In order to follow a novel approach to add on or to improve current vaccination strategies to mitigate STEC shedding by cattle, the objectives of this proof-of-concept study were to generate recombinant Shiga toxoids (rStx1mut & rStx2mut) by site-directed mutagenesis and to assess the immunomodulatory, antigenic, and immunogenic properties of the resulting proteins in cattle.
Material and methods
Generation of recombinant toxins and toxoids for in vitro and in vivo applications
Comparison of the gene sequences of Stx1 and Stx2 before and after mutagenesis
Relevant nucleotide sequence (codon triplets for amino acids 164 to 174 in 5′ to 3′ direction)*
Compared to wild type amino acid replacements on position †
-gtg aca gct gaa gct tta cgt ttt cgg caa ata-
-gtg aca gct Caa gct tta cTt ttt cgg caa ata-
-gtc aca gca gaa gcc tta cgc ttc agg cag ata-
-gtc aca gca Caa gcc tta cTc ttc agg cag ata-
Quantification of rStxWT was done by VCA and Stx ELISA (see below), quantification of rStxmut only by Stx ELISA. For adjustment of the vector control, the lowest dilution determined for rStxWT/rStxmut preparations to be applied in functional assays was also used for the vector control. The content of endotoxin was 51 fg/mL or less in rStxWT, rStxmut, and vector control preparations at working dilutions.
Vero cell cytotoxicity assay (VCA) and Vero cell cytotoxicity neutralization assay (VNA)
The VCA was performed in 96-well microtiter plates (Nunc, Wiesbaden, Germany) using Vero cells (ATCC CRL 1587, LGC-Promochem GmbH, Wesel, Germany) as previously described  to determine the cytotoxicity (verocytotoxic doses 50%, CD50/mL) of the rStxWT preparations and for adjustment of stock solutions (20 000 CD50/mL).
The VNA was used for the determination of the neutralization activity in serum of vaccinated calves and was done as previously described  in order to determine the titre of neutralizing antibodies [nAb titre] against either wild type Stx1 or wild type Stx2 (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany).
Enzyme-linked immunosorbent assay (ELISA)
To quantify rStx protein in the preparations, a commercial Stx ELISA was used (Novitec® Verotoxin ELISA-Test, HISS Diagnostics, Freiburg, Germany) following the manufactures instructions. rStxmut concentrations used for the functional assays were adjusted to reach an OD equivalent to the OD of rStxWT stock solutions containing 20 000 CD50/mL. Stock solutions were further diluted accordingly to reach a final concentration of 200 CD50/mL or equivalent doses.
Stx-specific antibodies in sera from naturally exposed calves collected during a proceeding study  were analysed in a modified form of the ELISA. Briefly, 19 serum samples with Stx1 nAb titres between 60 and 2000 (as determined by VNA) were pre-diluted to achieve an approx. 50% reduction of the relative optical density [ODrel]. Four serum samples with a Stx2 nAb titre of 30 were used un-diluted. Serum samples were incubated with either rStxWT or rStxmut preparations for 30 min at 37 °C. Subsequently, pre-incubated rStx was used as sample in the ELISA assay and subsequent steps were performed as described by the manufacturer. ODrel was calculated by the following formula: ODrel [%] = (ODrStx + serum sample - ODvector control + serum sample)/(ODrStx + negative serum - ODvector control + serum sample) × 100.
Primary cell cultures
Peripheral blood mononuclear cells (PBMC) were isolated as previously described . Cells were diluted in cell culture medium 1 (RPMI 1640, 10% fetal calf sera, 1% Penicillin/Streptomycin, 0.03% 1 mM 2-β-mercaptoethanol) to 1.5 × 106/mL and aliquoted into a 96-well flat-bottom plate (Greiner Bio-One, Frickenhausen, Germany) at 150 μL per well (2.25 × 105/well). Challenge material (rStxWT, rStxmut or vector control, respectively) was added to reach a final concentration of 200 CD50/mL or equivalent doses, respectively. For proliferation the mitogen phytohemagglutinin P [PHA-P] was added in a final concentration of 5 μg/mL. Plates were incubated for 96 h in 5% CO2 at 37 °C.
Ileal intraepithelial lymphocytes (iIEL) were isolated as described elsewhere . Cells were harvested and diluted in cell culture medium 2 (RPMI 1640, 20% fetal calf sera, 1% Penicillin/Streptomycin, 1% Amphotericin B, 0.01% Gentamicin) to 2 × 107/mL. Nine millilitre of this cell suspension were pipetted into a well of a 6-well plate and challenge material (rStxWT, rStxmut or vector control) was added to a final concentration of 200 CD50/mL or equivalent doses. Additionally, PHA-P was added to a final concentration of 2.5 μg/mL. Plates were incubated for 6 h in 5% CO2 at 37 °C.
Monocyte-derived macrophages (MDM) were isolated as described elsewhere [26,27]. Briefly, a whole blood sample was centrifuged (2380 × g, 20 min) and the buffy coat was collected. After several washing and lysis steps, buffy coat was layered onto Ficoll for density centrifugation (800 × g, 45 min). Cells were collected by taking the interphase and washed three times with PBS buffer. Cells were adjusted to 4 × 106/mL in cell culture medium 3 (Iscove’s Modified Dulbecco’s Medium (IMDM) without Phenol Red, 20% fetal calf sera, 1% Penicillin/Streptomycin, 1% Amphotericin B, 0.05% 100 mM 2-β-mercaptoethanol) and 25 mL of this cell suspension were transferred to Teflon bags (VueLife Bags, American Fluoroseal Corp., Gaithersburg, USA) and incubated for 8 days (37 °C, 5% CO2). At the end of the incubation period, cells were harvested and diluted to 2 × 106/mL in cell culture medium 4 (IMDM without phenol red, 2% fetal calf sera, 1% Penicillin/Streptomycin, 1% Amphotericin B, 0.05% 100 mM 2-β-mercaptoethanol). Five millilitre of the cell suspension was cultured in petri dishes (Greiner Bio-One, Frickenhausen, Germany) for 18 h. Lymphocytes were removed by careful washing and adherent MDMs were left within the dishes in cell culture medium 4. Challenge material was added in cell culture medium 4 to reach a final concentration of 200 CD50/mL or equivalent doses and incubated for 6 h.
At the end of the respective incubation times (see above), cells were resuspended and transferred to V-shape microtitre plates (Greiner Bio-One, Frickenhausen, Germany). After centrifugation (300 × g, 3 min, 4 °C) supernatants were flicked out. Pellets were resuspended in washing buffer (PBS supplemented with 1% bovine serum albumin, 0.01% sodium azide, and 0.5% goat serum) as negative control or with 50 μL of primary antibody dilution (diluted 1:50 through 1:500 in washing buffer). Antibodies were purchased from VMRD (Labor Diagnostik Leipzig, Leipzig, Germany; CD4 clone IL-A11, CD8β clone BAT82A, CD14 clone CAM36A, CD21 clone GB25A, γδT/N24 clone GB21A), AbDSerotech (Puchheim, Germany; CD77 clone 38–13) or kindly provided by Dirk Werling (The Royal Veterinary College, London, United Kingdom; CD80 clone N32/52-3, CD86 clone IL-A190). Cells were incubated for 20 min on ice, washed with washing buffer and resuspended in 50 μL of washing buffer with secondary antibodies (fluorescein isothiocyanate (FITC)-labelled α-rat IgM (Dianova GmbH, Hamburg, Germany); allophycocyanin (APC)-labelled α-mouse IgG1, APC-labelled α-mouse IgG2a, APC-labelled α-mouse IgG2b (Jackson ImmunoResearch Europe Ltd., Suffolk, United Kingdom)) supplemented with 7-amino actinomycin D (7-AAD; final concentration 2 μg/mL; Sigma-Aldrich, Taufkirchen, Germany). After 20 min on ice, cells were washed with washing buffer and analysed with BD FACSCalibur™ Analyzer (Becton-Dickinson, Heidelberg, Germany). For analysis of PBMC, following the last incubation step, cells were incubated with 50 μL of Annexin V-phycoerythrin[PE]-Dilution (1:500; Dianova GmbH, Hamburg, Germany), washed with Annexin V binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2), diluted in Annexin V binding buffer and analysed. Cells were gated according to their size and granularity. Only morphologically intact cells were used for further analysis. Cells positive for 7-AAD uptake or Annexin-V-PE binding were excluded and defined as early apoptotic (positive for Annexin-V-PE), late apoptotic (positive for Annexin-V-PE and 7-AAD), and necrotic (positive for 7-AAD), respectively. Data analysis was performed with FCSExpress (Version 2, De Novo-Software, Thornhill, Ontario, Canada).
At the end of the incubation period, iIEL were resuspended, transferred to 50 mL tubes, washed with PBS (200 × g, 7 min), lysed in 600 μL RLT buffer (RNeasy MiniKit, Qiagen, Hilden, Germany) supplemented with 1% β-mercaptoethanol, and stored at −70 °C.
All samples were thawed at 37 °C for 5 min, and then homogenized by passing through a 20 G needle. RNA isolation was performed with the RNeasy MiniKit following the manufacturers’ instruction with modifications described by Moussay et al. . Reverse transcription and real-time PCR using primers and probes labelled at the 5′-end with the reporter dye FAM (6-carboxyfluorescein) and at the 3′-end with the quencher dye TAMRA (6-carboxytetramethyl-rhodamine) was conducted as described . PCR amplification was performed on an automated fluorometer (ABI PRISM™ 5700 Sequence Detection System, Applied Biosystems) using 96-well optical plates. Each sample was analysed in duplicates. For analysis of the data, the comparative Ct method (ΔΔCt method) was applied with first, normalization of the Ct values referring to the housekeeping gene GAPDH and second, comparing the Ct values for the quantitation of IL-4-specific mRNA in cultures treated with challenge material (rStxWT, rStxmut) and in cultures treated with vector control (control cultures) .
The experiment was carried out in strict accordance with European and German laws for the care and use of animals, approved by Thüringer Landesamt für Lebensmittelsicherheit und Verbraucherschutz, Bad Langensalza, Germany (permit no. 22-268-04-04-105/11).
Prior to the experiment, two conventionally raised bull calves aged 11 months tested negative for Stx-specific antibodies (16 and 4 weeks before the trial by VNA). Calves were tested for STEC shedding 16 weeks before the trial and immediately prior to the 1st and the 2nd vaccination. For this purpose coliform bacteria from fecal samples were enriched by growth on Gassner agar (3 plates per sample) . Subsequently, the enriched bacterial culture material was tested with a stx1/stx2-duplex-PCR modified from Nguyen et al. . While all fecal samples were stx-negative at the first and last sampling, in both calves genes encoding Stx1 and Stx2 were present in the fecal sample taken prior to the 1st vaccination at low frequencies (only 1 of 3 enrichment cultures from these fecal samples tested positive). Calves were double-vaccinated i.m. with both, a rStx1mut vaccine and a rStx2mut vaccine on trial days 0 and 21. Immediately prior to application, vaccines had been freshly prepared as follows: rStx1mut and rStx2mut preparations were diluted separately with NaCl solution (0.89%) to 1 000 000 CD50 equivalents in 1.4 mL and then supplemented with 0.6 mL of aluminium hydroxide (Alu-Gel-S, Serva Electrophoresis GmbH, Heidelberg, Germany). Blood samples were taken weekly, centrifuged, and sera were frozen at −20 °C. Nine weeks after first immunization, last samples were drawn. Detection of specific antibodies in the sera was done by VNA. Titres below the detection limit were given an arbitrary value of 30.
Unless otherwise indicated, data obtained after applying rStxWT and rStxmut preparations in biological assays were normalized relative to data obtained after application of vector control.
Statistical analysis was done with “SPSS for windows” (Version 15, SPSS Inc., Chicago, Illinois, USA). Single factor variance analyses with repeated measurements were carried out applying Greenhouse Geisser Test for all data from in vitro testing of the preparations. Pearsons’s correlation analysis was used to compare quantitative values from the VNA. Two-tailed p-values with p ≤ 0.05 were considered significant. The following description was used: n.s. = not significant (p > 0.05); * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001.
Generation of Shiga toxins and toxoids
Viability and phenotype of bovine PBMC upon in vitro challenge with rStxWT and rStxmut
Purified wild type Stx1 from E. coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro without inducing cellular death . Neither incubation of PHA-P (phytohemagglutinin-P) stimulated PBMC with rStxWT nor incubation with rStxmut led to a significant increase in the percentage of late apoptotic/necrotic cells and the percentage of early apoptotic cells as compared to PHA-P stimulated bovine PBMC cultures incubated in the presence of the vector control (referred to as “control cultures” throughout; data not shown).
IL-4 transcription in bovine iIEL upon in vitro challenge with rStxWT and rStxmut
CD14 expression by bovine MDM upon in vitro challenge with rStxWT and rStxmut
Monocyte-derived macrophages (MDM) have recently been discovered as yet another Stx-sensitive cell type in cattle . Incubation with rStxWT or rStxmut for 6 h did not significantly alter the percentage of early apoptotic cells as compared control cultures (data not shown). However, MDM responded to the exposure to rStx1WT or rStx2WT with a clear decrease in the number of CD14 molecules on the cellular surface (as deduced from quantitation of fluorescence intensities (MFI) for the detection of this antigen). The effect was most prominent in the CD77 co-expressing subset of MDM (Figure 6B, data not shown for CD77− MDM). The recombinant toxins had no influence on the number of surface-expressed CD80 and CD86 molecules on CD77+ bovine MDM (data not shown). Incubation with comparable amounts of rStx1mut and rStx2mut had no significant effect on CD14, CD80, and CD86 expression by CD77+ bovine MDM (Figure 6B; data not shown for CD80 and CD86).
Recognition of rStxWT and rStxmut by sera from calves naturally exposed to wild type toxins
Immunization of calves with rStx1mut and rStx2mut
The immunomodulatory and -suppressive effects of Shiga toxins (Stx) disturb the development of an adaptive immune response against STEC-specific antigens in the course of the initial infection of that far naïve calves [11,12]. In order to develop an effective but biologically safe antigen to vaccinate cattle against the immunologically distinct types 1 and 2 of Stx the objectives of this study were to prove that recombinant Shiga toxoids devoid of the enzymatic activity of the wild type toxins have lost their activity against all types of bovine immune cells identified as potential Stx targets thus far. For functional studies, a concentration of rStx of 200 CD50/mL was chosen. Extensive previous studies had shown that purified Stx1 reliably induces maximum modulating effects on bovine immune cells in vitro at this concentration . Concentrations of 2000 CD50/mL may induce effects that cannot be fully neutralized by anti-StxB1 and therefore not clearly ascribed to Stx1 even when purified toxin is used . Partially purified (i.e., endotoxin-deprived) preparations were used in the current study causing some depression of the metabolic activity of the robust Vero cells when applied undiluted. As the aim of this study was to provide a broad proof of loss of immunomodulating function of rStxmut in bovines and experiments were exclusively conducted with primary cells availability of which was limited, we refrained from conducting dose–response assays for any of the parameters under study. Consequently, we cannot rule out the possibility that the toxoids may cause adverse effects when applied in significantly higher concentrations. However, efficient induction of a humoral immune response in two calves locally exposed to 1 000 000 CD50 equivalents upon vaccination points against such assumptions. Having accomplished this proof-of-principle study presented herein, an extensive experiment is currently under way assessing the immunomodulating, immunogenic, and protective capacity of rStxmut-based vaccines under field conditions.
Wild type Stx1 purified from a STEC field isolate blocks the proliferation of bovine peripheral blood T cells, with CD8+ T cells in particular, and induces a down-regulation of the Stx receptor CD77 on several lymphocyte subsets without inducing significant cell death by apoptosis or necrosis [11,13]. Results of the present study show that non-purified endotoxin-deprived periplasmic preparations containing recombinant rStxWT induce comparable biological effects in bovine PBMC cultures. Similar to studies with purified Stx1, addition of recombinant rStxWT containing periplasmic preparations did not significantly affect the overall percentage of early or late apoptotic/necrotic cells within major PBMC subsets. In-depth analysis of multicolour flow cytometry data, applied here for the first time, provided evidence, however, that rStxWT treatment has led to an increase in the portion of late apoptotic cells in all lymphocyte populations. Notably, this effect (1) predominantly affected the respective CD77+ expressing cells of the subsets and (2) could not be confirmed when analysing for early apoptotic cells. Further studies will be needed to dissect whether this effect can also be induced by purified toxins or is augmented by auxiliary factors present in the periplasmic preparations. Nevertheless, results presented here strongly imply that – despite several reports linking differences in the virulence of EHEC strains for humans to the Stx type or even subtype encoded for by the strains  - Stx1 and Stx2 do not differ significantly in their biological activities in bovines, the STEC/EHEC reservoir host, a finding that has direct implications for vaccine development.
Incubation of PBMC with rStx1mut and rStx2mut neither influenced the percentage of lymphocytes expressing CD77+ nor the overall subset composition. Toxoids did not induce a down-regulation of CD14 in MDM cultures and did not lead to an up-regulation of IL-4 transcription in iIEL cultures, effects that occurred in the presence of wild type toxins. Even though the molecular mechanism by which Stx induce cell death in a variety of cell lines and primary cells is well understood [33-35], the molecular basis of the immunomodulatory effects of wild type Stx to bovine immune cells is not entirely clear. In most cells, Stx primarily inhibit protein synthesis by acting on the 23S rRNA incorporated in ribosomes . THP-1 cells show an up-regulation of TNF-α upon treatment with Stx1 , an effect traced back to the ribotoxic stress response triggered by the enzymatic activity of Stx towards ribosomes. It would also be plausible that cross-linking of CD77 molecules on the cellular surfaces by the multivalent 5B plus 1A structured Stx has initiated cellular responses independent from the enzymatic activity as toxin binding induces apoptosis in sensitive cell lines . We previously showed that incubation of bovine iIEL neither with Stx1 holotoxin nor with purified Stx1B subunit or with anti-CD77 antibody induces IL-4 transcription . By contrast, binding of rStxB1 to CD77 on bovine PBMC induced a holotoxin like activity, e.g., an inhibition of lymphocyte proliferation . The results presented here using genetically modified Stx devoid of verocytotoxic activity as well as lacking any detectable biological activities of rStx1mut and rStx2mut in all in vitro systems applied strongly suggest that the enzymatic activity is essentially required for the immunomodulating effect of Stx in cattle and underscore that the toxoids may represent biologically safe vaccines.
Final prove of biological safety can only come from immunization trials in vivo. Of note, the interferon-α receptor (IFNAR) harbours potential binding sites for CD77 in its extracellular domains, structurally related to CD77 binding sites of StxB subunits  raising the possibility that Stx immunization may induce auto-antibodies. The detrimental potential of vaccine-induced auto-antibodies has become dramatically apparent by the occurrence of bovine neonatal panleucocytopenia (BNP). In this clinical entity, prevalent in several European countries in recent years, anti-leukocytic antibodies induced by vaccination of dams are transmitted to their offspring causing severe bleedings and bone marrow depletion . Anti-Stx1 antibodies can frequently be found in adult cattle [2,40] and anti-Stx2 antibodies, although with strikingly lower frequencies and titres, can also be detected. Two calves could be successfully vaccinated by two shots of vaccines containing rStx1mut and rStx2mut, and immunization did not exert adverse effects indicative of auto-antibodies.
Antigenicity of rStxmut was evaluated in comparison to rStxWT in a competitive ELISA format using sera obtained from naturally exposed calves with known anti-Stx1 and anti-Stx2 titres . Pre-incubation of the sera with rStxmut and rStxWT equally well reduced binding of the toxins to the capture antibodies. We take this as a strong hint that the structure of important epitopes being the target of a significant portion of naturally induced antibodies are conserved irrespective of the amino acid exchanges in the toxoids introduced by genetic modification.
To be used as vaccine component, inactivated Stx molecules must remain immunogenic. Chemical inactivation of Stx2e by formaldehyde treatment abolishes the cytotoxic effect in vitro but application of the toxoid failed to prevent piglets from developing edema disease upon intravenous challenge with wild type Stx2e . By contrast, inactivation of Stx2e by means of genetic amino acid exchange in the enzymatic cleft of the A subunit resulted in a vaccine able to induce protective antibodies in piglets . Similarly, the survival rate of mice after Stx1 challenge could be raised to 100% when animals had been immunized with mutagenized Stx1 (E167Q, R170L) . It remains unclear whether the poor induction of an anti-Stx response in cattle after natural STEC infection  is due to an active immunosuppression by Stx, due to an insufficient antigen exposure by small amounts of toxins produced in vivo or due to poor immunogenicity of the toxins. The latter may result from the structural similarity of StxB subunit with bovine IFNAR and be the consequence of a centrally induced immunological tolerance. Nevertheless, i.m. application to calves of the toxoids generated and characterized in this study led to the induction of substantial anti-Stx1 as well as anti-Stx2 titres, presumably protective in that they at least are able to neutralize the biological activity of Stx holotoxin in vitro. The study design applied here does not allow for concluding on the specificity of the antibodies to each of the toxoids. Kinetics of shedding of Stx1- and Stx2-producing STEC strains as well as kinetics and magnitude of maternal and endogenous anti-Stx antibodies in calves substantially differ . Further studies are worthwhile to separately optimize the immunogenic capacity of the two toxoids and to assess their relative protective efficacy, e.g., by modifications of the vaccine formulation and application scheme.
The STEC/EHEC pathovar consists of a plethora of different E. coli strains varying in serotype and virulence gene pattern. By definition, Stx’s are the only virulence factors harboured by all STEC strains. Up to now, success of attempts to vaccinate cattle was mostly restricted to single subpopulations of STEC, e.g. strains positive for O157 , harbouring the genes for Tir (translocated intimin receptor) , for adhesion factor intimin , Esp’s (E. coli secreted proteins) A and B [44,45] or flagellin H7 . Stx rather act as immunomodulating agents during bovine STEC infections [8-12] by affecting the early phases of immune activation than by depressing an established immunity [13,14]. Consequently, Stx may principally be effective upon first STEC infection of hitherto immunologically naïve animals at the time they first encounter STEC antigens. In the absence of Stx, animals may be able to mount an efficient adaptive immune response with the potential to prevent persistent STEC colonization of the intestinal mucosa. However, Stx always co-occurs with STEC antigens in spatial and temporal terms during infection. In this particular situation, Stx apparently hinders calves from properly responding, creating an immunologically privileged niche and thereby paving the way for persistent colonization. Application of Stx toxoid-based vaccines may enable calves to actively mount a primary immune response to antigens other than Stx that are harboured by STEC strains circulating in the respective cohort. In case future studies show that this does not suffice, subsequent application of aforementioned vaccines as booster shall be evaluated as to their ability to eventually induce a robust anti-STEC adaptive immune response mitigating long-term STEC shedding by cattle.
KK was in part financially supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) as part of the SFB535. The authors would like to thank U. Leidner (Institute of Hygiene and Infectious Diseases of Animals, Giessen, Germany) for her excellent technical assistance and the staff of the experimental animal facility (Friedrich-Loeffler-Institut, Jena, Germany) for their support during the animal trial.
- Caprioli A, Morabito S, Brugere H, Oswald E (2005) Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res 36:289–311View ArticlePubMedGoogle Scholar
- Fröhlich J, Baljer G, Menge C (2009) Maternally and naturally acquired antibodies to Shiga toxins in a cohort of calves shedding Shiga-toxigenic Escherichia coli. Appl Environ Microbiol 75:3695–3704View ArticlePubMed CentralPubMedGoogle Scholar
- Naylor SW, Gally DL, Low JC (2005) Enterohaemorrhagic E. coli in veterinary medicine. Int J Med Microbiol 295:419–441View ArticlePubMedGoogle Scholar
- Geue L, Segura-Alvarez M, Conraths FJ, Kuczius T, Bockemühl J, Karch H, Gallien P (2002) A long-term study on the prevalence of shiga toxin-producing Escherichia coli (STEC) on four German cattle farms. Epidemiol Infect 129:173–185View ArticlePubMed CentralPubMedGoogle Scholar
- Vande Walle K, Vanrompay D, Cox E (2013) Bovine innate and adaptive immune responses against Escherichia coli O157:H7 and vaccination strategies to reduce faecal shedding in ruminants. Vet Immunol Immunopathol 152:109–120View ArticlePubMedGoogle Scholar
- Snedeker KG, Campbell M, Sargeant JM (2012) A systematic review of vaccinations to reduce the shedding of Escherichia coli O157 in the faeces of domestic ruminants. Zoonoses Public Health 59:126–138View ArticlePubMedGoogle Scholar
- Mahajan A, Currie CG, Mackie S, Tree J, McAteer S, McKendrick I, McNeilly TN, Roe A, La Ragione RM, Woodward MJ, Gally DL, Smith DG (2009) An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157:H7 with bovine intestinal epithelium. Cell Microbiol 11:121–137View ArticlePubMedGoogle Scholar
- Stamm I, Mohr M, Bridger PS, Schröpfer E, König M, Stoffregen WC, Dean-Nystrom EA, Baljer G, Menge C (2008) Epithelial and mesenchymal cells in the bovine colonic mucosa differ in their responsiveness to Escherichia coli Shiga toxin 1. Infect Immun 76:5381–5391View ArticlePubMed CentralPubMedGoogle Scholar
- Moussay E, Stamm I, Taubert A, Baljer G, Menge C (2006) Escherichia coli Shiga toxin 1 enhances il-4 transcripts in bovine ileal intraepithelial lymphocytes. Vet Immunol Immunopathol 113:367–382View ArticlePubMedGoogle Scholar
- Menge C, Stamm I, Van Diemen PM, Sopp P, Baljer G, Wallis TS, Stevens MP (2004) Phenotypic and functional characterization of intraepithelial lymphocytes in a bovine ligated intestinal loop model of enterohaemorrhagic Escherichia coli infection. J Med Microbiol 53:573–579View ArticlePubMedGoogle Scholar
- Menge C, Wieler LH, Schlapp T, Baljer G (1999) Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro. Infect Immun 67:2209–2017PubMed CentralPubMedGoogle Scholar
- Hoffman MA, Menge C, Casey TA, Laegreid W, Bosworth BT, Dean-Nystrom EA (2006) Bovine immune response to shiga-toxigenic Escherichia coli O157:H7. Clin Vaccine Immunol 13:1322–1327View ArticlePubMed CentralPubMedGoogle Scholar
- Menge C, Stamm I, Wuhrer M, Geyer R, Wieler LH, Baljer G (2001) Globotriaosylceramide (Gb3/CD77) is synthesized and surface expressed by bovine lymphocytes upon activation in vitro. Vet Immunol Immunopathol 83:19–36View ArticlePubMedGoogle Scholar
- Stamm I, Wuhrer M, Geyer R, Baljer G, Menge C (2002) Bovine lymphocytes express functional receptors for Escherichia coli Shiga toxin 1. Microb Pathog 33:251–264View ArticlePubMedGoogle Scholar
- Kuribayashi T, Seita T, Fukuyama M, Furuhata K, Honda M, Matsumoto M, Seguchi H, Yamamoto S (2006) Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice. J Infect Chemother 12:251–256View ArticlePubMedGoogle Scholar
- Kuribayashi T, Seita T, Matsumoto M, Furuhata K, Tagata K, Yamamoto S (2009) Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs. Comp Med 59:163–167PubMed CentralPubMedGoogle Scholar
- Johnson RP, Cray WC, Jr, Johnson ST (1996) Serum antibody responses of cattle following experimental infection with Escherichia coli O157:H7. Infect Immun 64:1879–1883PubMed CentralPubMedGoogle Scholar
- MacLeod DL, Gyles CL (1991) Immunization of pigs with a purified Shiga-like toxin II variant toxoid. Vet Microbiol 29:309–318View ArticlePubMedGoogle Scholar
- Hovde CJ, Calderwood SB, Mekalanos JJ, Collier RJ (1988) Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc Natl Acad Sci U S A 85:2568–2572View ArticlePubMed CentralPubMedGoogle Scholar
- Yamasaki S, Furutani M, Ito K, Igarashi K, Nishibuchi M, Takeda Y (1991) Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic Escherichia coli for toxin activity. Microb Pathog 11:1–9View ArticlePubMedGoogle Scholar
- Makino S, Watarai M, Tabuchi H, Shirahata T, Furuoka H, Kobayashi Y, Takeda Y (2001) Genetically modified Shiga toxin 2e (Stx2e) producing Escherichia coli is a vaccine candidate for porcine edema disease. Microb Pathog 31:1–8View ArticlePubMedGoogle Scholar
- Ohmura-Hoshino M, Yamamoto M, Yuki Y, Takeda Y, Kiyono H (2004) Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity. Vaccine 22:3751–3761View ArticlePubMedGoogle Scholar
- Ishikawa S, Kawahara K, Kagami Y, Isshiki Y, Kaneko A, Matsui H, Okada N, Danbara H (2003) Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect Immun 71:3235–3239View ArticlePubMed CentralPubMedGoogle Scholar
- Gentry MK, Dalrymple JM (1980) Quantitative microtiter cytotoxicity assay for Shigella toxin. J Clin Microbiol 12:361–366PubMed CentralPubMedGoogle Scholar
- Menge C, Blessenohl M, Eisenberg T, Stamm I, Baljer G (2004) Bovine ileal intraepithelial lymphocytes represent target cells for Shiga toxin 1 from Escherichia coli. Infect Immun 72:1896–1905View ArticlePubMed CentralPubMedGoogle Scholar
- Adler H, Peterhans E, Jungi TW (1994) Generation and functional characterization of bovine bone marrow-derived macrophages. Vet Immunol Immunopathol 41:211–227View ArticlePubMedGoogle Scholar
- Werling D, Howard CJ, Niederer E, Straub OC, Saalmüller A, Langhans W (1998) Analysis of the phenotype and phagocytic activity of monocytes/macrophages from cattle infected with the bovine leukaemia virus. Vet Immunol Immunopathol 62:185–195View ArticlePubMedGoogle Scholar
- Barth S, Duncker S, Hempe J, Breves G, Baljer G, Bauerfeind R (2009) Escherichia coli Nissle 1917 for probiotic use in piglets: evidence for intestinal colonization. J Appl Microbiol 107:1697–1710View ArticlePubMedGoogle Scholar
- Nguyen TV, Le Van P, Le Huy C, Gia KN, Weintraub A (2005) Detection and characterization of diarrheagenic Escherichia coli from young children in Hanoi, Vietnam. J Clin Microbiol 43:755–760View ArticlePubMed CentralPubMedGoogle Scholar
- Menge C, Stamm I, Blessenohl M, Wieler LH, Baljer G (2003) Verotoxin 1 from Escherichia coli affects Gb3/CD77+ bovine lymphocytes independent of interleukin-2, tumor necrosis factor-alpha, and interferon-alpha. Exp Biol Med 228:377–386Google Scholar
- Loos D (2012) Untersuchungen zum Einfluss von Shigatoxin auf Makrophagen und dendritische Zellen des Rindes. Doctoral thesis, Justus Liebig University Gießen, Institute of Hygiene and Infectious Diseases of Animals.
- Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, Karch H (2002) Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 185:74–84View ArticlePubMedGoogle Scholar
- O’Loughlin EV, Robins-Browne RM (2001) Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infect 3:493–507View ArticlePubMedGoogle Scholar
- Karmali MA (2004) Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 26:117–122View ArticlePubMedGoogle Scholar
- Foster GH, Tesh VL (2002) Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-alpha. J Leukoc Biol 71:107–114PubMedGoogle Scholar
- Obrig TG, Moran TP, Brown JE (1987) The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244:287–294PubMed CentralPubMedGoogle Scholar
- Harrison LM, van Haaften WC, Tesh VL (2004) Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect Immun 72:2618–2627View ArticlePubMed CentralPubMedGoogle Scholar
- Maloney MD, Binnington-Boyd B, Lingwood CA (1999) Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt’s lymphoma cells. Glycoconj J 16:821–828View ArticlePubMedGoogle Scholar
- Bridger PS, Bauerfeind R, Wenzel L, Bauer N, Menge C, Thiel HJ, Reinacher M, Doll K (2011) Detection of colostrum-derived alloantibodies in calves with bovine neonatal pancytopenia. Vet Immunol Immunopathol 141:1–10View ArticlePubMedGoogle Scholar
- Pirro F, Wieler LH, Failing K, Bauerfeind R, Baljer G (1995) Neutralizing antibodies against Shiga-like toxins from Escherichia coli in colostra and sera of cattle. Vet Microbiol 43:131–141View ArticlePubMedGoogle Scholar
- Gordon VM, Whipp SC, Moon HW, O’Brien AD, Samuel JE (1992) An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect Immun 60:485–490PubMed CentralPubMedGoogle Scholar
- Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, Erickson G, Hinkley S, Klopfenstein T, Moxley RA, Smith DR, Finlay BB (2004) Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 22:362–369View ArticlePubMedGoogle Scholar
- van Diemen PM, Dziva F, Abu-Median A, Wallis TS, van den Bosch H, Dougan G, Chanter N, Frankel G, Stevens MP (2007) Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H. Vet Immunol Immunopathol 116:47–58View ArticlePubMed CentralPubMedGoogle Scholar
- Dziva F, Vlisidou I, Crepin VF, Wallis TS, Frankel G, Stevens MP (2007) Vaccination of calves with EspA, a key colonisation factor of Escherichia coli O157:H7, induces antigen-specific humoral responses but does not confer protection against intestinal colonisation. Vet Microbiol 123:254–261View ArticlePubMedGoogle Scholar
- Bretschneider G, Berberov EM, Moxley RA (2007) Isotype-specific antibody responses against Escherichia coli O157:H7 locus of enterocyte effacement proteins in adult beef cattle following experimental infection. Vet Immunol Immunopathol 118:229–238View ArticlePubMedGoogle Scholar
- McNeilly TN, Naylor SW, Mahajan A, Mitchell MC, McAteer S, Deane D, Smith DG, Low JC, Gally DL, Huntley JF (2008) Escherichia coli O157:H7 colonization in cattle following systemic and mucosal immunization with purified H7 flagellin. Infect Immun 76:2594–2602View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.